Supplementary Online Content
|
|
- Calvin Stafford
- 5 years ago
- Views:
Transcription
1 Supplementary Online Content Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. Published online June 30, doi: /jamaoncol emethods. Search Strategy etable 1. Study Quality of Eligible Trials etable 2. Summary of Toxicities efigure 1. Flowchart for Manuscript Selection efigure 2. Neoadjuvant Hormone Therapy vs Neoadjuvant Cytotoxic Chemotherapy efigure 3. Neoadjuvant Aromatase Inhibitors vs Neoadjuvant Tamoxifen efigure 4. Neoadjuvant Endocrine Therapy vs Dual Therapy efigure 5. Funnel Plots for Studies Evaluating Neoadjuvant Therapies This supplementary material has been provided by the authors to give readers additional information about their work.
2 emethods. Search Strategy Ovid MEDLINE(R) 1 exp Breast neoplasms/ or (breast adj2 cancer).ti,ab. or (breast adj2 malig*).ti,ab. or breast neoplasm*.ti,ab. 2 Tamoxifen/ or exp Selective Estrogen Receptor Modulators/ or (Femara or tamoxifen or letrozole or anastrozole or Arimidex or exemestane or Aromasin or Selective Estrogen Receptor Modulators* or serm or fulvestrant or Faslodex or endocrine therap* or endocrine treat*).ti,ab. 3 Neoadjuvant Therapy/ or Preoperative Care/ or (neo adjuvant or neoadjuvant or nat or Preoperative or presurg*4 or pre operative or pre surg*4).ti,ab. 4 Neoplasm Staging/ or (tumor stag* or tumour stag* or cancer stag* or neoplasm stag* or stage i or stage ii or stage iii or local*4 or locally advanced or LABC).ti,ab. 5 (hormone receptor positive or estrogen receptor positive or hr positive or er positive or er+ or hr+).ti,ab. 6 Disease-Free Survival/ or treatment outcome/ or Dose-Response Relationship, Drug/ or (treatment outcome* or clinical response* or drug Dose Response Relationship* or pathological* complete response* or pcr or Disease-Free Survival or surviv*).ti,ab. 7 (controlled clinical trial or meta analysis or randomized controlled trial or review).pt. or Intervention Studies/ or (intervention studies or intervention study or systematic or ebm or evidence).ti,hw. 8 exp Neoplasm Metastasis/ or (Metastasis or metastases or metastatic).ti,ab. or sc.fs. 9 1 and 2 and 3 and (4 or 5 or 6) and not 8
3 11 limit 10 to (english language and humans) PubMed ((Neoadjuvant Therapy[mesh] OR (neoadjuvant endocrine OR neoendocrine[tiab]) AND (breast cancer[tiab] or breast malignancy*[tiab] or breast tumor*[tiab] or breast tumour*[tiab] or breast neoplasms[mesh] or stage i breast[tiab] or stage ii breast[tiab] or stage iii breast[tiab] or localized breast[tiab] or localised breast[tiab] NOT (metastasis OR metastases OR secondary OR lcis OR dcis)). Limited to English
4 etable 1. Study Quality of Eligible Trials Author and trial name (if applicable) Year Study described as randomized? Randomization method described and appropriate? Study described as double blind? Method of double blinding described and appropriate? Description of withdrawals and dropouts? Jadad Score (0-5) Alba GEICAM/ Palmieri 2012 Yes Yes Not applicable Not applicable Yes Yes Yes Not applicable Not applicable Yes 3 NEOCENT Semiglazov 2007 Yes Yes Not applicable Not applicable Yes 3 Eiermann 2001 Yes Yes Yes Not described Yes 4 P024 Smith 2005 Yes Not reported Yes Yes Yes 4 IMPACT Masuda 2012 Yes Yes Yes Yes Yes 5 STAGE Cataliotti 2006 Yes Not reported Yes Yes Yes 4
5 Ellis 2001 Yes Yes Yes Yes Yes 5 Miller 2001 Yes No Not applicable Not applicable No 1 Harper- Wynne 2002 Yes Not reported Not applicable Not applicable Yes 2 Guarneri 2014 Yes Yes Yes Yes Yes 5 Baselga 2009 Yes Not reported Yes Yes Yes 4 Chow 2008 Yes Yes Not applicable Not applicable Yes 3 CAAN Smith 2007 Yes Not reported Not applicable Not applicable Yes 2 Hojo 2013 Yes Not reported Not applicable Not applicable Yes 2 PTEX46 Kuter 2012 Yes Not reported Not applicable Not applicable Yes 2 NEWEST Ellis 2011 Yes Not reported Not applicable Not applicable Yes 2 ACOSOG Z1031 Polychronis 2005 Yes Yes Yes Yes Yes 5
6 Fasching 2014 Yes Not reported Not applicable Not applicable Yes 2 FemZone Mohammadianpanah 2011 Yes Not reported Not applicable Not applicable Yes 2
7 etable 2. Summary of Toxicities Author and trial name (if applicable) Year Experimental arm agent(s) Control arm agent(s) Toxicities Alba GEICAM/ Exemestane 25 mg daily + goserelin 3.6 mg/month if premenopausal EC-T: Epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 4 cycles q21d docetaxel 100 mg/m2 4 cycles q21d + goserelin 3.6 mg/month if premenopausal 47% of patients given CT had grade 3 4 toxicity (excluding amenorrhea) based on NCI-CTCAE 3.0, compared with 9% of patients receiving HT (P < 0.001). Patients receiving CT experienced more gastrointestinal toxicity, leukopenia, and neutropenia, with a febrile neutropenia rate of 7%. Palmieri NEOCENT 2014 Letrozole 2.5 mg daily FEC: 5-fluorouracil mg/m2 + epirubicin mg/m2 + cyclophosphamide mg/m2 x 6 cycles q21d; switched to docetaxel 100 mg/m2 after 3 cycles if SD or PD (N = 11) Statistically significant differences between treatment groups favoring letrozole were seen in relation to alopecia, nausea, vomiting, stomatitis and anemia. There were eight serious adverse reactions, all occurring in those who received CT. Six were neutropenia-related.
8 Semiglazov 2007 Anastrozole 1 mg daily or exemestane 25 mg daily Doxorubicin 60 mg/m2 + paclitaxel 200 mg/m2 x 4 cycles q21d The incidence of commonly reported adverse events was higher in patients who receiving CT. No serious adverse events were reported in patients who were receiving HT. Six patients who were receiving CT experienced febrile neutropenia that led to treatment interruption. Eiermann P Letrozole 2.5 mg daily Tamoxifen 20 mg daily The nature and frequency of commonly reported AEs was the same for the letrozole and tamoxifen groups (57% in each group). The most commonly reported AEs related to study treatment were hot flushes and nausea. Smith IMPACT 2005 Anastrozole 1 mg daily; Anastrozole 1 mg daily + Tamoxifen 20 mg daily Tamoxifen 20 mg daily All treatments were generally well tolerated. The most common adverse event in all groups was hot flashes, with a nonsignificant trend towards a lower incidence with anastrozole (18%) than with tamoxifen (26%) or the combination (28%). The only significant difference was in vaginal discharge, which was not reported in any patient on anastrozole (0%) compared with 6% of patients on tamoxifen and 8% of patients on the combination.
9 Masuda STAGE 2012 Anastrozole 1 mg daily + goserelin 3.6 mg/month Tamoxifen 20 mg daily + goserelin 3.6 mg/month Treatment-related AEs were reported by 84% patients in the anastrozole group and 77% patients in the tamoxifen group, with the majority being grade 1 or 2. 50% of patients in the anastrozole group reported musculoskeletal and connect tissue disorder AEs compared to 30% in the tamoxifen group. Cataliotti 2006 Anastrozole 1 mg daily Tamoxifen 20 mg daily Both anastrozole and tamoxifen were well tolerated. AEs considered to be study related were reported in 20.2% of patients in the anastrozole group and 18.1% of patients in the tamoxifen group. Ellis 2001 Letrozole 2.5 mg daily Tamoxifen 20 mg daily Not reported Miller 2001 Anastrozole 1 mg daily (n = 12) or 10 mg daily (n = 11) Tamoxifen 40 mg daily Not reported Harper-Wynne 2002 Vorozole 2.5 mg daily Tamoxifen 20 mg daily Not reported Guarneri 2014 Letrozole 2.5 mg daily and lapatinib 1500 mg daily Letrozole 2.5 mg daily and placebo Skin disorders, diarrhea, and liver function test abnormalities occurred more frequently in lapatinib-treated patients. One episode of grade 4 skin toxicity was reported in one patient randomly assigned to the letrozole-lapatinib arm.
10 Baselga 2009 Letrozole 2.5 mg daily and everolimus 10 mg daily Chow CAAN 2008 Examestane 25 mg daily and celecoxib 400 mg twice daily Smith 2007 Anastrozole 1 mg daily and gefitinib 250 mg daily (combined 2 arms, gefitinib 14 vs. 16 weeks) Hojo PTEX46 Kuter NEWEST 2013 Exemestane 25 mg daily 2012 Fulvestrant 500 mg/month mg on day 14 of month 1 Letrozole 2.5 mg daily and placebo Exemestane 25 mg daily; letrozole 2.5 mg daily Anastrozole 1 mg daily Exemestane 25 mg daily Fulvestrant 250 mg/month The safety profile was described as consistent with historical results of everolimus monotherapy: grades 3 to 4 AEs occurred in 22.6% of patients who received everolimus and in 3.8% of patients who received placebo. Dose reduction or interruption as a result of an AE occurred in 52.9% of the everolimus-treated patients versus 7.6% of the placebo-treated patients. One patient (4%) from the exemestane monotherapy group experienced grade 3 hot flashes. No other serious and/or severe adverse event was reported in the study. 13% of patients assigned to gefitinib and anastrozole discontinued treatment because of AEs, compared with 2% receiving anastrozole alone. Not reported Both treatments were well tolerated. Treatment-related AEs were experienced by 37.4 and 30.7% of patients and treatment-related serious AEs by 0.9 and 3.0% of patients in the fulvestrant 500 mg and fulvestrant 250 mg groups, respectively.
11 Ellis ACOSOG Z Exemestane 25 mg daily Letrozole 2.5 mg daily; anastrozole 1 mg daily No severe toxicity was reported by more than 5% of the patients. The most common grade 2 toxicity was hot flashes/flushes. Polychronis 2005 Gefitinib 250 mg daily and anastrozole 1 mg daily Gefitinib 250 mg daily and placebo Gefitinib was well tolerated as a single agent and in combination with anastrozole. Mild WHO grade 1 2 adverse events seen in both groups were felt to be consistent with the known safety profiles of gefitinib and anastrozole. Treatment was interrupted for 3 11 days in three patients in the gefitinib-alone group because of transient grade 1 diarrhea in two patients and grade 1 skin toxicity and abdominal symptoms in one patient. The addition of anastrozole did not exacerbate the adverse effects of gefitinib. Fasching FemZone 2014 Letrozole 2.5 mg daily and zoledronic acid 4mg IV q4w Letrozole 2.5 mg daily 81% of patients reported grade 1 or 2 AEs in the letrozole only arm and 87.6% in the letrozole + zoledronic acid arm. For grade 3 or 4 AEs, 8.9% were reported in the letrozole only arm and 19.1% in the letrozole + zoledronic acid arm. Most frequent side effects were musculoskeletal disorders, hot flushes, skin and gastrointestinal disorders.
12 Mohammadianpanah 2011 Letrozole 2.5 mg daily + FAC (5FU 600 mg/m2 + doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2) q21d FAC (5FU 600 mg/m2 + doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2) q21d Common treatment-related side effects such as nausea, vomiting, bone marrow suppression, and mucositis were similar in both groups, but hot flush was more prevalent in the CT/HT arm compared with the CT arm (P = 0.023). Q21d: every 21 days; q4w: every 4 weeks; CT: chemotherapy; HT: hormone therapy; NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; AEs: adverse events; WHO: World Health Organization.
13 efigure 1. Flowchart for Manuscript Selection Publications assessed for eligibility (N = 477) Excluded (N = 450) based on abstract review Duplications (N = 200) Did not meet criteria (N = 250) Full texts reviewed (N = 27) RCTs excluded (N =7) Duplicate (N = 1) Lack of data (N = 1) Incorrect outcome (N = 5) RCTs included (N = 20) CT x HT with AI (N = 3) HT plus CT x CT (N = 1) HT with tamoxifen x HT with AI (N = 6) HT with tamoxifen x HT with AI x HT with tamoxifen/ai (N = 1) HT with AI of differing durations (N = 1) HT with SERD of differing doses (N = 1) HT with 3 different AIs (N = 1) HT and other agents (N = 6) Abbreviations: RCTs, Randomized controlled trials; CT, Chemotherapy; HT, Hormone therapy; AI, Aromatase inhibitor; TAM, Tamoxifen; SERD, Selective estrogen receptor degrader.
14 efigure 2. Neoadjuvant Hormone Therapy vs Neoadjuvant Cytotoxic Chemotherapy efigure 2A. Comparison of clinical response (fixed effects model). efigure 2B. Comparison of clinical response (Peto odds ratio method). efigure 2C. Comparison of clinical response (random effects model).
15 efigure 2D. Comparison of imaging response (fixed effects model). efigure 2E. Comparison of imaging response (Peto odds ratio method). efigure 2F. Comparison of imaging response (random effects model). efigure 2G. Comparison of pathologic complete response (fixed effects model).
16 efigure 2H. Comparison of pathologic complete response (Peto odds ratio method). efigure 2I. Comparison of pathologic complete response (random effects model). efigure 2J. Comparison of rates of breast conservation surgery (fixed effects model). efigure 2K. Comparison of rates of breast conservation surgery (Peto odds ratio method).
17 efigure 2L. Comparison of rates of breast conservation surgery (random effects model). Abbreviations: M-H, Mantel-Haenzel method; CI, Confidence interval; df, Degrees of freedom
18 efigure 3. Neoadjuvant Aromatase Inhibitors vs Neoadjuvant Tamoxifen efigure 3A. Comparison of clinical response (fixed effects model). efigure 3B. Comparison of imaging response (fixed effects model).
19 efigure 3C. Comparison of pathologic complete response (fixed effects model). efigure 3D. Comparison of rates of breast conservation surgery (fixed effects model). Abbreviations: M-H, Mantel-Haenzel method; CI, Confidence interval; df, Degrees of freedom; AI, aromatase inhibitor.
20 efigure 4. Neoadjuvant Endocrine Therapy vs Dual Therapy efigure 4A. Comparison of clinical response (fixed effects model). efigure 4B. Comparison of clinical response (Peto odds ratio method). efigure 4C. Comparison of clinical response (random effects model).
21 efigure 4D. Comparison of imaging response (fixed effects model). efigure 4E. Comparison of imaging response (Peto odds ratio method). efigure 4F. Comparison of imaging response (random effects model).
22 efigure 4G. Comparison of clinical response for neoadjuvant endocrine therapy versus dual therapy with a growth factor pathway inhibitor (fixed effects model). efigure 4H. Comparison of clinical response for neoadjuvant endocrine therapy versus dual therapy with a growth factor pathway inhibitor (Peto odds ratio method). efigure 4I. Comparison of clinical response for neoadjuvant endocrine therapy versus dual therapy with a growth factor pathway inhibitor (random effects method).
23 efigure 4J. Comparison of imaging response for neoadjuvant endocrine therapy versus dual therapy with a growth factor pathway inhibitor (fixed effects model). efigure 4K. Comparison of imaging response for neoadjuvant endocrine therapy versus dual therapy with a growth factor pathway inhibitor (Peto odds ratio method). efigure 4L. Comparison of imaging response for neoadjuvant endocrine therapy versus dual therapy with a growth factor pathway inhibitor (random effects model). Abbreviations: M-H, Mantel-Haenzel method; CI, Confidence interval; df, Degrees of freedom; GFI = Growth Factor pathway Inhibitor.
24 efigure 5. Funnel Plots for Studies Evaluating Neoadjuvant Therapy Funnel Plot for Studies Evaluating Neoadjuvant Hormone Therapy vs Neoadjuvant Cytotoxic Chemotherapy efigure 5A. Studies evaluating clinical response efigure 5B. Studies evaluating imaging response
25 Funnel Plot for Studies Evaluating Neoadjuvant Aromatase Inhibitors vs Dual Therapy efigure 5C. Studies evaluating clinical response efigure 5D. Studies evaluating imaging response
Lessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationBREAST CANCER RISK REDUCTION (PREVENTION)
BREAST CANCER RISK REDUCTION (PREVENTION) Articles Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationDocetaxel plus Cyclophosphamide as Adjuvant Therapy for Early, Operable Breast Cancer
CED-SOS Advice Report 9 EDUCATION AND INFORMATION 2012 Docetaxel plus Cyclophosphamide as Adjuvant Therapy for Early, Operable Breast Cancer M. Trudeau and J. Franek A Quality Initiative of the Program
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationOnline-Only Supplementary Materials
Online-Only Supplementary Materials Online-Only Supplementary Methods: Eligibility Criteria and Study Endpoints and Assessments Supplementary Table 1. Demographic and Baseline Characteristics in Patients
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationTargeted Agents In Breast Cancer. Wonderful Music With New Instruments
Targeted Agents In Breast Cancer Wonderful Music With New Instruments 1 Trends In Cancer Mortality In Women in US At This Rate We Will Beat Breast Cancer In 2040 Is the cause screening?? Is the cause better
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationNIH Public Access Author Manuscript Nat Rev Clin Oncol. Author manuscript; available in PMC 2012 December 10.
NIH Public Access Author Manuscript Published in final edited form as: Nat Rev Clin Oncol. ; 9(4): 223 229. doi:10.1038/nrclinonc.2012.21. Use of neoadjuvant data to design adjuvant endocrine therapy trials
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationMETASTATIC BREAST CANCER: CONTROLLING THE HERD WHEN THE HORSES ARE OUT OF THE BARN
METASTATIC BREAST CANCER: CONTROLLING THE HERD WHEN THE HORSES ARE OUT OF THE BARN V A L L E R I E G O R D O N B S C, M D, F R C P C M E D I C A L O N C O L O G I S T A S S I S T A N T P R O F E S S O
More informationTherapy Side Effects
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Therapy Side Effects Therapy Side Effects Versions 2004 2011: Albert / Bischoff / Costa / Friedrichs / Göhring / Jackisch/
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationAdvances in Neoadjuvant and Adjuvant Therapy for Breast Cancer
Advances in Neo and Adjuvant Therapy for Breast Cancer Nicole Kounalakis, MD, and Christina Finlayson, MD OVERVIEW Systemic therapy for breast cancer is evolving rapidly. The medical treatment of cancer
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationSession Breast Cancer. Alessandra Fabi Il punto di vista dell esperto
Session Breast Cancer Alessandra Fabi Il punto di vista dell esperto Roma 6-7.10.2017 The Importance of Understanding What Disease to Treat Cejalvo et al, Cancer Res 2017 Skyline Chaging at evolution of
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationLuminal early breast cancer: (neo-) adjuvant endocrine therapy
CAMPUS GROSSHADERN CAMPUS INNENSTADT KLINIK UND POLIKLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE DIREKTOR: PROF. DR. MED. SVEN MAHNER Luminal early breast cancer: (neo-) adjuvant endocrine therapy Nadia
More informationThe Latest Research: Hormonal Therapies
The Latest Research: Hormonal Therapies Sameer Gupta, M.D., M.P.H 9/29/2018 Attending Physician, Hematology/Oncology Bryn Mawr Hospital Clinical Assistant Professor, Jefferson Medical College Disclosures
More informationThe efficacy of second-line hormone therapy for recurrence during adjuvant hormone therapy for breast cancer
517734TAM6210.1177/1758834013517734Therapeutic Advances in Medical OncologyR Mori and Y Nagao research-article2013 Therapeutic Advances in Medical Oncology Original Research The efficacy of second-line
More informationClinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
ORIGINAL ARTICLE 2018 Mar 16. [Epub ahead of print] Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Mi Hwa Heo, Hee Kyung Kim,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationSystemic Treatment of Breast Cancer. Hormone Therapy and Chemotherapy, Curative and Palliative
Systemic Treatment of Breast Cancer Hormone Therapy and Chemotherapy, Curative and Palliative Systemic Therapy Invasive breast cancers Two forms Curative Palliative Curative Systemic Therapy Adjuvant Therapy
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cortazar P, Zhang L, Untch M, et al. Pathological
More informationUpdate from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002
Update from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002 Nearly 5,000 physicians, oncologists, radiologists, epidemiologists, basic scientists, and breast cancer advocates from
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationVinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Original article Annals of Oncology 14: 699 703, 2003 DOI: 10.1093/annonc/mdg199 Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationShould premenopausal HR+ve breast cancer receive LHRH?
Should premenopausal HR+ve breast cancer receive LHRH? Hesham Elghazaly, MD Prof. Clinical Oncology, Ain Shams University President of the BGICS Should premenopausal HR+ve breast cancer receive LHRH? NO?
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationA Layperson's Guide to Endocrine (Hormone) Therapy
A Layperson's Guide to Endocrine (Hormone) Therapy What we will cover What is the endocrine system Basic definition of endocrine therapy Classes of endocrine drugs How you can utilise endocrine therapy
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationTerapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro
Terapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro Unit of Investigative Clinical Oncology Istituto di Candiolo (IRCCS) Disclosures Speaker s Honoraria
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationFor more information, call AstraZeneca Access 360 at ASK-A360, Monday through Friday, 8:00 AM to 8:00 PM ET.
1-844-ASK-A360 1-844-275-2360 1-844-FAX-A360 1-844-329-2360 www.myaccess360.com For more information, call AstraZeneca Access 360 at 1-844-ASK-A360, Monday through Friday, 8:00 AM to 8:00 PM ET. Indications
More informationSupplementary information
Supplementary information Network Meta-Analysis of The Effectiveness of Neoadjuvant Endocrine Therapy for postmenopausal, HR Positive Breast Cancer Wei Wang 1*, Chenghao Liu *, Wenbin Zhou 1, Tiansong
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationSupplementary Online Content
Supplementary Online Content Chawla SP, Papai Z, Mukhametshina G, et al. First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized
More informationObesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities Sao Jiralerspong and Pamela J. Goodwin
VOLUME 34 NUMBER 35 DECEMBER 10, 2016 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities Sao Jiralerspong and Pamela J.
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationIntroduction. Ahmad Radzi 1*, Fabian Wei Luen Lee 2 REVIEW ARTICLE
doi: 10.18282/amor.v4.i1.255 REVIEW ARTICLE Optimizing treatment-sequencing strategies for the management of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: A
More informationClinical Practice Guidelines - Breast Disease Site
Date: (O): (R): Jan 31, 2014 Tumor Group: Breast Disease Site Group Page: 1 of 11 Issuing Authority: Dr. Jehann Siddiqui Clinical Chief, Cancer Care Program Date Signed: July 4, 2014 Adapted From: Up To
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationThe Pharmacist s Role in Breast Cancer Awareness and Treatment
The Pharmacist s Role in Breast Cancer Awareness and Treatment James A. Trovato, Pharm.D., BCOP Associate Professor University of Maryland School of Pharmacy This program has been supported by an educational
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationObjectives Primary Objectives:
Z1031 A randomized phase III trial comparing 16 to 18 weeks of neoadjuvant exemestane (25mg daily), letrozole (2.5mg), or anastrozole (1mg) in postmenopausal women with clinical stage II and III estrogen
More informationIssues in Cancer Survivorship. Larissa A. Korde, MD, MPH June 26, 2010
Issues in Cancer Survivorship Larissa A. Korde, MD, MPH June 26, 2010 Estimated US Cancer Cases in Women: 2006-2008 CA Cancer J Clin 2006; 56:106-130; CA Cancer J Clin 2008;58:71 96. Relative Survival*
More informationUpdate from the 29th Annual San Antonio Breast Cancer Symposium
Update from the 29th Annual San Antonio Breast Cancer Symposium The San Antonio Breast Cancer Symposium is one of the most important breast cancer conferences. Approximately 8,000 physicians, oncologists,
More informationA review of adjuvant hormonal therapy in
REVIEW Endocrine-Related Cancer (2004) 11 391 406 A review of adjuvant hormonal therapy in breast cancer Kellie L Jones and Aman U Buzdar 1 Department of Pharmacy, University of Texas M.D. Anderson Cancer
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More informationREFERENCE NUMBER: NH.PST.05 EFFECTIVE DATE: 10/10
PAGE: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationSupplementary Online Content
Supplementary Online Content Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. doi:10.1001/jama.2016.21038 Additional
More information